Epigral Limited has scheduled a one-on-one meeting with Bellwether Capital through video conferencing on June 16, 2026. The company stated that the interaction is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. No unpublished price sensitive information will be shared during the discussion.

The meeting details were communicated to the National Stock Exchange of India Limited and BSE Limited. The schedule is subject to change due to exigencies on the part of the institutional investors or the company.

Meeting Details

The latest Earnings Presentation and Corporate Presentation relevant to the discussion are available on the company's official website. Gaurang Trivedi, Company Secretary and Compliance Officer, signed the disclosure on June 10, 2026.

InCred has downgraded epigral to a Reduce rating, setting a target price of ₹915. The brokerage's revised stance reflects a confluence of structural and operational headwinds that are seen weighing on the company's near-term financial performance.

Key Reasons Behind the Downgrade

The downgrade is underpinned by multiple concerns spanning both external market dynamics and company-specific operational factors. The following table summarises the primary drivers cited by InCred:

Oversupply and Margin Pressures

A central concern flagged by InCred is the rising downside risk from Chinese oversupply in caustic soda and epichlorohydrin (ECH). Excess supply from China in these key chemical segments is seen as a significant external headwind that could compress realisations and weigh on Epigral's revenue trajectory. This oversupply dynamic, combined with falling gross margins, points to a challenging pricing environment for the company's core product portfolio.

Operational and Financial Headwinds

Beyond the external supply-side pressures, InCred highlights company-specific concerns that add to the cautious outlook. Epigral's high earnings sensitivity, stemming from its large capacity exposure, means that any shortfall in volumes or pricing could have an outsized impact on profitability. The slower utilisation ramp-up of capacities further compounds this risk, as the company may take longer than anticipated to achieve optimal operating leverage. Declining return ratios and peaking EPS growth round out the brokerage's concerns, suggesting that the financial performance improvement cycle may be moderating.